Your activity: 8 p.v.

Albendazole: Drug information

Albendazole: Drug information
(For additional information see "Albendazole: Patient drug information" and see "Albendazole: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Albenza [DSC]
Pharmacologic Category
  • Anthelmintic
Dosing: Adult
Ancylostoma caninum

Ancylostoma caninum (eosinophilic enterocolitis) (off-label use): Oral: 400 mg as a single dose (Drugs for Parasitic Infections 2013).

Ancylostoma duodenale or Necator americanus

Ancylostoma duodenale or Necator americanus (hookworms) (off-label use): Oral: 400 mg as a single dose (Drugs for Parasitic Infections 2013; Steinmann 2011).

Ascariasis

Ascariasis (intestinal roundworm) (off label): Oral: 400 mg as a single dose (Drugs for Parasitic Infections 2013).

Clonorchis sinensis or Opisthorchis viverrini

Clonorchis sinensis (Chinese liver fluke) or Opisthorchis viverrini (Southeast Asian liver fluke) (off-label use): Oral: 10 mg/kg/day for 7 days (Drugs for Parasitic Infections 2013).

Cutaneous larva migrans

Cutaneous larva migrans (dog and cat hookworm) (off-label use): Oral: 400 mg once daily for 3 days (Drugs for Parasitic Infections 2013).

Enterobiasis

Enterobiasis (pinworm) (off-label use): Oral: 400 mg as a single dose; repeat in 2 weeks (Drugs for Parasitic Infections 2013).

Giardiasis

Giardiasis (Giardia duodenalis ) (alternative agent) (off-label use): Oral: 400 mg once daily for 5 days (Drugs for Parasitic Infections 2013; Karabay 2004).

Gnathostomiasis

Gnathostomiasis (Gnathostoma spinigerum) (off-label use): Oral: 400 mg twice daily for 21 days (Drugs for Parasitic Infections 2013).

Gongylonemiasis

Gongylonemiasis (Gongylonema spp.) (off-label use): Oral: 400 mg once daily for 3 days (Drugs for Parasitic Infections 2013).

Hydatid disease

Hydatid disease (Echinococcus granulosis, dog tapeworm) : Oral:

<60 kg: 15 mg/kg/day in 2 divided doses (maximum: 800 mg/day).

≥60 kg: 800 mg/day in 2 divided doses.

Duration: Optimal duration uncertain; 1 to 6 months based on clinical factors (Drugs for Parasitic Infections 2013).

Microsporidiosis

Microsporidiosis (off-label use):

Immunocompetent patients:

Disseminated infection: Oral: 400 mg twice daily (Drugs for Parasitic Infections 2013).

Intestinal (Encephalitozoon intestinalis) infection: Oral: 400 mg twice daily for 21 days (Drugs for Parasitic Infections 2013).

Ocular infection: Oral: 400 mg twice daily, in combination with topical fumagillin (Drugs for Parasitic Infections 2013).

Immunocompromised patients (eg, patients with HIV):

Disseminated or intestinal infection (other than Enterocytozoon bieneusi or Vittaforma corneae): Oral: 400 mg twice daily for 21 days (HHS [OI Adults 2019]; La Hoz 2019); for patients with HIV, continue until CD4 count >200 cells/mm3 for >6 months after initiation of antiretroviral therapy (HHS [OI Adults 2019]).

Ocular infection: Oral: 400 mg twice daily, in combination with topical fumagillin; continue until resolution of ocular symptoms and until CD4 count >200 cells/mm3 for >6 months after initiation of antiretroviral therapy (HHS [OI Adults 2019]).

Neurocysticercosis, parenchymal disease

Neurocysticercosis (Taenia solium, pork tapeworm), parenchymal disease: Oral: 15 mg/kg/day in 2 divided doses (maximum: 1.2 g/day) for 10 to 14 days; may be repeated if persistent viable lesions on 6-month follow-up imaging. Note: Concomitant therapy with praziquantel is recommended if >2 viable cysts present (Garcia 2014; IDSA/ASTMH [White 2018]; WHO 2021). Initiate adjunctive corticosteroid therapy prior to initiation of albendazole. Antiparasitic therapy should not be initiated in patients with untreated hydrocephalus, calcified lesions, or cysticercal encephalitis; consult an infectious diseases specialist for specific treatment recommendations (IDSA/ASTMH [White 2018]).

Oesophagostomum bifurcum

Oesophagostomum bifurcum (off-label use): Oral: 400 mg as a single dose (Ziem 2004).

Taeniasis

Taeniasis (alternative agent) (off label): Oral: 400 mg once daily for 3 days (CDC 2022; PAHO 2021).

Toxocariasis

Toxocariasis (off-label use):

Ocular larva migrans with sight-threatening ocular inflammation: Oral: Optimal dose is unknown: 400 mg twice daily for 2 weeks (Jee 2016); 800 mg twice daily has also been described (Barisani-Asenbauer 2001). Give with concomitant corticosteroids (Barisani-Asenbauer 2001; Jee 2016).

Visceral larva migrans, moderate to severe: Oral: 400 mg twice daily generally for 5 days; consider concomitant corticosteroids for severe infection (Drugs for Parasitic Infections 2013).

Trichinellosis

Trichinellosis (Trichinella spiralis) (off-label use): Oral: 400 mg twice daily for 8 to 14 days; concomitant corticosteroids may be given for severe symptoms (Drugs for Parasitic Infections 2013).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, the need for adjustment not likely since albendazole is primarily eliminated by hepatic metabolism.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in manufacturer's labeling. However, patients with underlying liver disease may be more at risk for adverse effects.

Dosing: Pediatric

(For additional information see "Albendazole: Pediatric drug information")

Ascariasis

Ascariasis (intestinal roundworm): Limited data available:

Children ≤2 years: Oral: 200 mg as a single dose; may repeat in 3 weeks (WHO 2010).

Children >2 years and Adolescents: Oral: 400 mg as a single dose; may repeat in 3 weeks (Parasitic Infections 2013; Red Book [AAP 2018]; WHO 2010).

Baylisascaris procyonis, postexposure prophylaxis and treatment

Baylisascaris procyonis (raccoon roundworm), postexposure prophylaxis and treatment: Limited data available:

Children and Adolescents: Oral: Frequently reported dose: 40 mg/kg/day (range: 20 to 50 mg/kg/day) in a single or 2 divided doses or 400 mg twice daily. Initiate as soon as possible after potential exposure (ideally within 3 days) to prevent clinical disease in any child at risk (eg, ingestion of raccoon stool or contaminated soil). Duration for prophylaxis is at least 10 days. Reported treatment duration is usually 4 weeks (Gavin 2002; Graeff-Teixeira 2016; Hajek 2009; Murray 2004; Pai 2007; Park 2000; Peters 2012).

Capillariasis

Capillariasis: Limited data available: Children and Adolescents: Oral: 400 mg once daily for at least 10 days (CDC 2020; Parasitic Infections 2013; Sawamura 1999).

Enterobiasis

Enterobiasis (pinworm): Limited data available:

Children ≤2 years: Oral: 200 mg as a single dose; may repeat in 3 weeks (WHO 2010).

Children >2 years and Adolescents: Oral: 400 mg as a single dose; repeat in 2 to 3 weeks (Bradley 2019; Red Book [AAP 2018]; WHO 2010).

Giardiasis

Giardiasis (Giardia duodenalis) (alternative therapy): Limited data available: Children ≥2 years and Adolescents: Oral: 10 mg/kg/dose once daily for 5 days; maximum dose: 400 mg/dose (Parasitic Infections 2013; Yereli 2004).

Hookworm, zoonotic

Hookworm, zoonotic (cutaneous larva migrans) (Ancylostoma braziliense, Ancylostoma caninum, Ancylostoma ceylanicum, Uncinaria stenocephala):

Infants ≥8 months: Very limited data available: Oral: 200 mg once daily for 3 days. Dosing based on 4 cases (ages 8, 11, 12, and 13 months) of infants who showed clinical improvement after therapy. There was complete resolution of infection in 2 of these infants; one infant had initial improvement, then recurrence requiring a second course of therapy and eventually alternate therapy, and another infant had resolution of symptoms followed by appearance of a similar lesion at a different location 3 months later, received a second course, and had rapid resolution of all symptoms (Black 2010).

Children and Adolescents: Limited data available: Oral: 15 mg/kg/dose once daily for 3 days; maximum dose: 400 mg/dose (Bradley 2019; CDC 2020; Red Book [AAP 2018]; WHO 2010).

Hookworms, human

Hookworms, human (Ancylostoma duodenale or N. americanus) :

Infants ≥3 months: Very limited data available: Oral: 200 mg as a single dose. Dosing based on two cases (patient #1: age: 12 weeks, weight: 4.2 kg; and patient #2: age: 8 months, weight: 5.8 kg) of exclusively breastfed infants who showed clinical improvement after single-dose albendazole therapy (Bhatia 2010).

Children ≤2 years: Limited data available: Oral: 200 mg as a single dose; may repeat in 3 weeks (WHO 2007; WHO 2010).

Children >2 years and Adolescents: Limited data available: Oral: 400 mg as a single dose; may repeat in 3 weeks (Red Book [AAP 2018]; WHO 2007; WHO 2010).

Hydatid disease

Hydatid disease (E. granulosus, dog tapeworm): Children and Adolescents: Oral: 5 to 7.5 mg/kg/dose twice daily for 1 to 6 months; maximum dose: 400 mg/dose (CDC 2020; Red Book [AAP 2018]).

Liver flukes

Liver flukes (C. sinensis or O. viverrini): Limited data available: Children and Adolescents: Oral: 10 mg/kg/dose once daily for 7 days (CDC 2020; Parasitic Infections 2013).

Microsporidia infection

Microsporidia infection (except Enterocytozoon spp. and Vittaforma corneae): Limited data available:

Children and Adolescents: Oral: 7.5 mg/kg/dose twice daily; maximum dose: 400 mg/dose (HHS [pediatric 2016]; Parasitic Infections 2013) in HIV-exposed/-infected, continue until resolution of signs and symptoms and sustained immune reconstitution (>6 months at CDC immunologic category 1 or 2) after antiretroviral therapy initiation (HHS [pediatric 2019]).

Neurocysticercosis, parenchymal disease

Neurocysticercosis (T. solium, pork tapeworm), parenchymal disease: Note: Patients should receive concurrent corticosteroid for the first week of albendazole therapy and antiseizure medication therapy as required.

Children and Adolescents: Oral: 7.5 mg/kg/dose twice daily for 8 to 30 days; maximum dose: 600 mg/dose (IDSA/ASTMH [White 2018]; Red Book [AAP 2018]; manufacturer's labeling). Note: Guidelines recommend treating for 10 to 14 days and addition of praziquantel if >2 viable cysts present (IDSA/ASTMH [White 2018]).

Strongyloidiasis

Strongyloidiasis ( S. stercoralis ): Limited data available: Children and Adolescents: Oral: 400 mg twice daily for 7 days (Bradley 2019; Parasitic Infections 2013; Red Book [AAP 2018]).

Toxocariasis

Toxocariasis: Limited data available:

Ocular larva migrans: Oral: Children and Adolescents: 400 mg twice daily for 10 to 14 days in combination with corticosteroids (Barisani-Asenbaur 2001; Frazier 2009; Red Book [AAP 2018]); durations of up to 4 weeks have also been reported (Bradley 2019; Parasitic Infections 2013).

Visceral larva migrans: Oral: Children and Adolescents: 400 mg twice daily for 5 days (Bradley 2019; CDC 2020; Parasitic Infections 2013; Red Book [AAP 2018]).

Trichinellosis

Trichinellosis (Trichinosis): Limited data available: Children and Adolescents: Oral: 400 mg twice daily for 8 to 14 days (CDC 2020; Parasitic Infections 2013; WHO 2010).

Trichuriasis

Trichuriasis (whipworm): Limited data available: Children >2 years and Adolescents: Oral: 400 mg once daily for 3 days (Parasitic Infections 2013; WHO 2010); mild cases may be treated with a single dose of 200 to 400 mg; may repeat course in 3 weeks (WHO 2010).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, the need for adjustment not likely since albendazole is primarily eliminated by hepatic metabolism.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; consider discontinuing therapy if hepatic enzymes increase to twice the ULN while on therapy.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Albenza: 200 mg [DSC]

Albenza: 200 mg [DSC] [contains saccharin sodium]

Generic: 200 mg

Generic Equivalent Available: US

Yes

Administration: Adult

Oral: Administer with a high-fat meal if treating a systemic infection (to increase absorption). Administration on an empty stomach may be appropriate for treating an intraluminal infection with no systemic involvement (Lange 1988). If patients have difficulty swallowing, tablets may be crushed or chewed, then swallowed with a drink of water.

Administration: Pediatric

Oral: Administer with a high-fat meal to increase absorption. For patients who have difficulty swallowing whole tablets, tablet may be crushed or chewed and swallowed with a drink of water.

Use: Labeled Indications

Hydatid disease (Echinococcus granulosus, dog tapeworm): Treatment of cystic hydatid disease of the liver, lung, and peritoneum caused by the larval form of the dog tapeworm, E. granulosus.

Neurocysticercosis (Taenia solium, pork tapeworm), parenchymal disease: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, T. solium.

Use: Off-Label: Adult

Ancylostoma caninum (eosinophilic enterocolitis); Ancylostoma duodenale or Necator americanus (hookworms); Ascariasis (intestinal roundworm); Clonorchis sinensis (Chinese liver fluke) or Opisthorchis viverrini (Southeast Asian liver fluke); Cutaneous larva migrans (dog and cat hookworm); Enterobiasis (pinworm); Giardiasis (Giardia duodenalis); Gnathostomiasis (Gnathostoma spinigerum); Gongylonemiasis (Gongylonema spp.); Microsporidiosis; Oesophagostomum bifurcum; Toxocariasis; Trichinellosis (Trichinella spiralis)

Medication Safety Issues
Sound-alike/look-alike issues:

Albenza may be confused with Aplenzin, Relenza.

International issues:

Albenza [US] may be confused with Avanza brand name for mirtazapine [Australia].

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Central nervous system: Headache (neurocysticercosis: 11%; hydatid: 1%)

Hepatic: Increased liver enzymes (hydatid: 16%; neurocysticercosis: <1%)

1% to 10%:

Central nervous system: Increased intracranial pressure (≤2%), dizziness (≤1%), vertigo (≤1%), meningism (1%)

Dermatologic: Alopecia (<1% to 2%)

Gastrointestinal: Abdominal pain (≤6%), nausea and vomiting (4% to 6%)

Miscellaneous: Fever (≤1%)

<1%, postmarketing, and/or case reports: Acute hepatic failure, acute renal failure, agranulocytosis, aplastic anemia, erythema multiforme, granulocytopenia, hepatitis, hypersensitivity reaction, leukopenia, neutropenia, pancytopenia, skin rash, Stevens-Johnson syndrome, thrombocytopenia, urticaria

Contraindications

Hypersensitivity to albendazole, benzimidazoles, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Agranulocytosis, aplastic anemia, granulocytopenia, leukopenia, and pancytopenia have occurred leading to fatalities (rare); use with caution in patients with hepatic impairment (more susceptible to hematologic toxicity). Discontinue therapy in all patients who develop clinically significant decreases in blood cell counts.

• Transaminase elevations: Reversible elevations in hepatic enzymes have been reported. Patients with abnormal LFTs and hepatic echinococcosis are at an increased risk of hepatotoxicity. Discontinue therapy if LFT elevations are >2 times the upper limit of normal; may consider restarting treatment (with frequent monitoring of LFTs) when hepatic enzymes return to pretreatment values. Discontinue therapy if hepatic enzymes are significantly increased.

Disease-related concerns:

• Neurocysticercosis: Appropriate use: Antiparasitic therapy may worsen symptoms of neurocysticercosis by inducing an inflammatory response; adjunctive corticosteroid therapy should be started before initiation of albendazole. Antiparasitic therapy should not be initiated in patients with untreated hydrocephalus, calcified lesions, or cysticercal encephalitis. Perform funduscopic exam prior to initiation of antiparasitic therapy to exclude intraocular cysticerci; antiparasitic therapy may lead to blindness in some cases with unsuspected intraocular parasites (IDSA/ASTMH [White 2018]).

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

CarBAMazepine: May decrease serum concentrations of the active metabolite(s) of Albendazole. Risk C: Monitor therapy

Grapefruit Juice: May increase serum concentrations of the active metabolite(s) of Albendazole. Risk C: Monitor therapy

Nirmatrelvir and Ritonavir: May decrease the serum concentration of Albendazole. Risk C: Monitor therapy

PHENobarbital: May decrease serum concentrations of the active metabolite(s) of Albendazole. Risk C: Monitor therapy

Phenytoin: May decrease serum concentrations of the active metabolite(s) of Albendazole. Risk C: Monitor therapy

Ritonavir: May decrease the serum concentration of Albendazole. Risk C: Monitor therapy

Food Interactions

Albendazole serum levels may be increased if taken with a fatty meal (increases the oral bioavailability by up to 5 times). Management: Should be administered with a high-fat meal when treating systemic infections.

Reproductive Considerations

Evaluate pregnancy status prior to use in females of reproductive potential. Effective contraception is recommended during chronic therapy (Persichino 2018) and for 1 month after the last dose (per the manufacturer).

The World Health Organization recommends preventive therapy with a benzimidazole, such as albendazole, in females of reproductive potential who live in areas where the baseline prevalence of soil-transmitted helminth infections is ≥20% (WHO 2017).

Pregnancy Considerations

Information following first trimester use of albendazole is limited (Gyorkos 2019; Lau 2020). Most pregnancy outcome information is available from studies using a single dose of albendazole administered to women during the second or third trimester (Gyorkos 2019; Lau 2020; Mofid 2017; Salam 2015). However, case reports are also available following longer term treatment of hydatid disease (Auer 1994; Bhattacharyya 2013; Pallua 2010).

Untreated soil-transmitted helminth infections during pregnancy are associated with adverse maternal outcomes (eg, maternal iron deficiency anemia, impaired nutrient absorption) (WHO 2017).

Use during the first trimester of pregnancy is not recommended (HHS [OI Adult 2019]; IDSA/ASTMH [White 2018]; WHO 1996; WHO 2017). Pregnant patients with neurocysticercosis should be treated for symptoms (eg, increased intracranial pressure, seizures) the same as nonpregnant patients; however, antihelminthic therapy with albendazole can be deferred until after delivery (IDSA/ASTMH [White 2018]). Albendazole should not be used for the treatment of microsporidiosis in HIV-infected pregnant patients during the first trimester; use later in pregnancy may be considered when the benefits outweigh potential risks (HHS [OI Adult 2019]; White 2018). The WHO also recommends treatment of soil-transmitted helminthiases (such as hookworm) in pregnant patients after the first trimester (WHO 1996). Pregnant women arriving as refugees from specific countries should not be given albendazole for the presumptive treatment of intestinal parasites prior to arrival in the United States (CDC 2019).

Breastfeeding Considerations

Albendazole is present in breast milk.

Albendazole excretion into breast milk was studied following a single oral 400 mg dose in breastfeeding women 2 weeks' to 6 months' postpartum (n=33). Mean albendazole concentrations 6 hours after the dose were 63.7 ± 11.9 ng/mL (maternal serum) and 31.9 ± 9.2 ng/mL (milk). An active and inactive metabolite were also detected in breast milk (Abdel-tawab 2009).

A case report describes use of albendazole for the treatment of hydatid disease of the breast in a lactating woman (Siddiqui 2015).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. However, albendazole is generally considered compatible with breastfeeding (WHO 2002). Breastfeeding women arriving as refugees from specific countries may be given albendazole for the presumptive treatment of intestinal parasites (CDC 2019).

Monitoring Parameters

LFTs and CBC with differential at start of each 28-day cycle and every 2 weeks during therapy (more frequent monitoring for patients with liver disease); pregnancy test

Patients with neurocysticercosis: Ophthalmic exam for retinal lesions prior to therapy initiation; MRI every 6 months after completing therapy until resolution of cystic lesion (IDSA/ASTMH [White 2018])

Mechanism of Action

Active metabolite, albendazole sulfoxide, causes selective degeneration of cytoplasmic microtubules in intestinal and tegmental cells of intestinal helminths and larvae; glycogen is depleted, glucose uptake and cholinesterase secretion are impaired, and desecratory substances accumulate intracellulary. ATP production decreases causing energy depletion, immobilization, and worm death.

Pharmacokinetics

Note: In pediatric patients (6-13 years), pharmacokinetic values were reported to be similar to adult data.

Absorption: Poor from the GI tract; may increase up to 5 times when administered with a fatty meal

Distribution: Widely distributed throughout the body including urine, bile, liver, cyst wall, cyst fluid, and CSF

Protein binding: 70%

Metabolism: Hepatic; extensive first-pass effect; pathways include rapid sulfoxidation to active metabolite (albendazole sulfoxide [major]), hydrolysis, and oxidation

Half-life elimination: 8 to 12 hours (albendazole sulfoxide)

Time to peak, serum: 2 to 5 hours for the metabolite

Excretion: Urine (<1% as active metabolite); feces

Pharmacokinetics: Additional Considerations

Hepatic function impairment: Systemic availability, rate of absorption, and the elimination half-life of albendazole sulfoxide are increased in patients with extrahepatic obstruction.

Pricing: US

Tablets (Albendazole Oral)

200 mg (per each): $18.00 - $276.65

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Abentel (BD, CN, TH);
  • ABZ (IN, ZW);
  • Acure (PK);
  • Adazol (EC);
  • Albatel (TH);
  • Alben (BR);
  • Alben-VC (TH);
  • Albenda (AE, BH, KW, LB, QA, SA);
  • Albentel (PE);
  • Albentox (LK);
  • Albenzol (EC);
  • Albenzole (EG);
  • Albex (AE, CY, IQ, IR, JO, KW, LB, LK, LY, OM, QA, SA, SY, VN, YE);
  • Albezole (IN);
  • Albi (KR);
  • Aldaben (BD);
  • Aldazol (PH);
  • Alfuca (TH);
  • Allbacom (KR);
  • Almex (MY);
  • Alminth (IN);
  • Alzental (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SG, SY, VN, YE);
  • Alzol (TH);
  • Andazol (TR);
  • Anhelmin (UA);
  • Ascarol (EC);
  • Ben A (BD);
  • Bendax (EG);
  • Bendex (ET);
  • Bendex-400 (ZA);
  • Benzol (PH);
  • Bruzol (CR, DO, GT, HN, MX, NI, PA, SV);
  • Buxol (CR, DO, GT, HN, NI, PA, SV);
  • CB-400 (TH);
  • Ciclopar (CO);
  • Cystazole (JO);
  • Dalben (HR);
  • Daxol Plus (PY);
  • Dazole (LK);
  • Digezanol (MX);
  • Emanthal (IN);
  • Eskasole (MX);
  • Eskazole (AT, AU, DE, ES, GB, GR, IL, JP, NL);
  • Estazole (LK);
  • Falben (TH);
  • Fintel (PE);
  • Frantel (VN);
  • Gascop (MX);
  • Gelmodol (RU);
  • Gloalbendazole (KR);
  • Helmiben (UY);
  • Helmidazole (AE, CY, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);
  • Hyemex (PH);
  • Labenda (TH);
  • Lokaben (LK);
  • Lomsin (MX);
  • Lurdex (MX);
  • Mebenix (BR);
  • Mitizen 200 (VN);
  • Mitizen 400 (VN);
  • Nematel (AR);
  • Nemozole (IN, RU, ZW);
  • Olworm (LK);
  • Ovis (ET);
  • Oxal (MX);
  • Pantex (PY);
  • Paranthil (ZA);
  • Parhel (CR, DO, GT, HN, NI, PA, SV);
  • Rex (KR);
  • Rotopar (EC);
  • Sanoxal (RU);
  • Sintel (BD);
  • Sioban (IN);
  • Temizol (PY);
  • Thelban (MY);
  • Unizol (SV);
  • Valbazen Vet (NO);
  • Vastus (AR);
  • Vemizol (MY);
  • Vermicet (AR);
  • Vermin Plus (MX);
  • Vermizol (EG);
  • Vermizole (AR);
  • Vetoben (TH);
  • Vormil (UA);
  • Wormed (ZW);
  • Zeben (TH);
  • Zela (TH);
  • Zental (RO);
  • Zentel (AE, AU, BB, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CY, CZ, EC, ET, FR, GH, GM, GN, GT, GY, HN, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, OM, PA, PE, PL, PR, PT, QA, SA, SC, SD, SG, SI, SK, SL, SN, SR, SY, TH, TN, TT, TZ, UA, UG, VE, VN, YE, ZA, ZM, ZW);
  • Zestaval (TR, ZW)


For country code abbreviations (show table)
  1. Albendazole tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; May 2020.
  2. Albenza (albendazole) tablets [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; September 2019.
  3. Abdel-tawab AM, Bradley M, Ghazaly EA, et al, "Albendazole and its Metabolites in the Breast Milk of Lactating Women Following a Single Oral Dose of Albendazole," Br J Clin Pharmacol, 2009, 68(5):737-42. [PubMed 19916998]
  4. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.
  5. Auer H, Kollaritsch H, Jüptner J, Aspöck H. Albendazole and pregnancy. Appl Parasitol. 1994;35(2):146-147. [PubMed 8087155]
  6. Baird RA, Wiebe S, Zunt JR, et al, “Evidence-Based Guideline: Treatment of Parenchymal Neurocysticercosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology,” Neurology, 2013, 80(15):1424-9. [PubMed 23568997]
  7. Baranwal AK, Singhi PD, Khandelwal N, et al, “Albendazole Therapy in Children With Focal Seizures and Single Small Enhancing Computerized Tomographic Lesions: A Randomized, Placebo-Controlled, Double Blind Trial,” Pediatr Infect Dis J, 1998, 17(8):696-700. [PubMed 9726343]
  8. Barisani-Asenbauer T, Maca SM, Hauff W, et al. Treatment of ocular toxocariasis with albendazole. J Ocul Pharmacol Ther. 2001;17(3):287-294. doi: 10.1089/108076801750295317. [PubMed 11436948]
  9. Bethony J, Brooker S, Albonico M, et al, “Soil-Transmitted Helminth Infections: Ascariasis, Trichuriasis, and Hookworm,” Lancet, 2006, 367(9521):1521-32. [PubMed 16679166]
  10. Bhatia V, Das MK, Kumar P, Arora NK. Infantile hookworm disease. Indian Pediatr. 2010;47(2):190-192. [PubMed 20228435]
  11. Bhattacharyya SK, Bhattacharya S, Alam H, Patua B, Chattopadhyay P. Dilemmas encountered while dealing a pregnancy complicated by pelvic Hydatid disease. Arch Gynecol Obstet. 2013;288(5):965-966. [PubMed 23625356]
  12. Black MD, Grove DI, Butcher AR, Warren LJ. Cutaneous larva migrans in infants in the Adelaide Hills. Australas J Dermatol. 2010;51(4):281-284. [PubMed 21198527]
  13. Bradley JS, Nelson JD, Barnett ED, et al, eds. Nelson's Pediatric Antimicrobial Therapy. 25th ed. American Academy of Pediatrics; 2019.
  14. Centers for Disease Control and Prevention (CDC) parasite website. https://www.cdc.gov/parasites/index.html. Accessed November 11, 2016.
  15. Centers for Disease Control and Prevention (CDC). Parasites - Cysticercosis. Available at http://www.cdc.gov/parasites/cysticercosis/health_professionals/index.html#drugs. Updated April 2016.
  16. Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. MMWR Recomm Rep. 2009;58(RR-11):1-166. [PubMed 19730409]
  17. Centers for Disease Control and Prevention (CDC). Guidelines for overseas presumptive treatment of strongyloidiasis, schistosomiasis, and soil-transmitted helminth infections for refugees resettling to the United States. February 2019. https://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/intestinal-parasites-overseas.html.
  18. Centers for Disease Control and Prevention (CDC). Parasites. https://www.cdc.gov/parasites/index.html. Updated August 19, 2022. Accessed August 31, 2022.
  19. Del Brutto OH, Roos KL, Coffey CS, et al, “Meta-Analysis: Cysticidal Drugs for Neurocysticercosis: Albendazole and Praziquantel,” Ann Intern Med, 2006, 145(1):43-51. [PubMed 16818928]
  20. de Silva N, Guyatt H, and Bundy D, “Anthelmintics. A Comparative Review of Their Clinical Pharmacology,” Drugs, 1997, 53(5):769-88. [PubMed 9129865]
  21. Drugs for Parasitic Infections. Med Lett Drugs Ther. 2013. 11(suppl):e1-e31.
  22. Frazier M, Anderson ML, Sophocleous S. Treatment of ocular toxocariasis with albendezole: a case report. Optometry. 2009;80(4):175-180. [PubMed 19329060]
  23. Garcia HH, Gilman RH, Horton J, et al, “Albendazole therapy for neurocysticercosis: A Prospective Double-Blind Trial Comparing 7 Versus 14 Days of Treatment,” Neurology, 1997, 48(5):1421-7. [PubMed 9153484]
  24. Garcia HH, Gonzales I, Lescano AG, et al; Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(8):687-695. doi: 10.1016/S1473-3099(14)70779-0. [PubMed 24999157]
  25. Garcia HH, Pretell EJ, Gilman RH, “A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis,” N Engl J Med, 2004, 350(3):249-58. [PubMed 14724304]
  26. Gavin PJ, Kazacos KR, Tan TQ, et al. Neural larva migrans caused by the raccoon roundworm Baylisascaris procyonis. Pediatr Infect Dis J. 2002;21(10):971-975. doi:10.1097/00006454-200210000-00017 [PubMed 12394823]
  27. Graeff-Teixeira C, Morassutti AL, Kazacos KR. Update on Baylisascariasis, a Highly Pathogenic Zoonotic Infection. Clin Microbiol Rev. 2016;29(2):375-399. [PubMed 26960940]
  28. Gyorkos TW, St-Denis K. Systematic review of exposure to albendazole or mebendazole during pregnancy and effects on maternal and child outcomes, with particular reference to exposure in the first trimester. Int J Parasitol. 2019;49(7):541-554. [PubMed 31071321]
  29. Hajek J, Yau Y, Kertes P, et al. A child with raccoon roundworm meningoencephalitis: A pathogen emerging in your own backyard?. Can J Infect Dis Med Microbiol. 2009;20(4):e177-e180. doi:10.1155/2009/304625 [PubMed 21119798]
  30. Hawk MW, Shahlaie K, Kim KD, and Theis JH, “Neurocysticercosis: A Review,” Surg Neurol, 2005, 63(2):123-32. [PubMed 15680651]
  31. Jee D, Kim KS, Lee WK, Kim W, Jeon S. Clinical features of ocular toxocariasis in adult Korean patients. Ocul Immunol Inflamm. 2016;24(2):207-216. doi: 10.3109/09273948.2014.994783. [PubMed 25564736]
  32. Jung H, Sanchez M, Gonzalez-Astiazaran A, et al, “Clinical Pharmacokinetics of Albendazole in Children With Neurocysticercosis,” Am J Ther, 1997, 4(1):23-6. [PubMed 10423586]
  33. Karabay O, Tamer A, Gunduz H, Kayas D, Arinc H, Celebi H. Albendazole versus metronidazole treatment of adult giardiasis: an open randomized clinical study. World J Gastroenterol. 2004;10(8):1215-1217. doi: 10.3748/wjg.v10.i8.1215. [PubMed 15069729]
  34. La Hoz RM, Morris MI; AST Infectious Diseases Community of Practice. Intestinal parasites including cryptosporidium, cyclospora, giardia, and microsporidia, entamoeba histolytica, strongyloides, schistosomiasis, and echinococcus: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13618. doi: 10.1111/ctr.13618. [PubMed 31145496]
  35. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol. 1988;34(3):315-317. [PubMed 3396623]
  36. Lau R, Chris RB, Phuong MS, et al. Treatment of soil-transmitted helminth infections in pregnancy: a systematic review and meta-analysis of maternal outcomes. J Travel Med. 2020;27(2). doi:10.1093/jtm/taz079 [PubMed 31641774]
  37. Liu LX and Weller PF, “Antiparasitic Drugs,” N Engl J Med, 1996, 334(18):1178-84. [PubMed 8602186]
  38. Mofid LS, Casapía M, Aguilar E, et al. A double-blind randomized controlled trial of maternal postpartum deworming to improve infant weight gain in the Peruvian Amazon. PLoS Negl Trop Dis. 2017;11(1):e0005098. [PubMed 28056024]
  39. Murray WJ, Kazacos KR. Raccoon roundworm encephalitis. Clin Infect Dis. 2004;39(10):1484-1492. [PubMed 15546085]
  40. Pai PJ, Blackburn BG, Kazacos KR, Warrier RP, Bégué RE. Full recovery from Baylisascaris procyonis eosinophilic meningitis. Emerg Infect Dis. 2007;13(6):928-930. [PubMed 17553240]
  41. Pallua K, Putz G, Mitterschiffthaler G, Brezinka C, Biebl M, Paal P. Management of hepatic echinococcosis in pregnancy. Int J Gynaecol Obstet. 2010;109(2):162. [PubMed 20176353]
  42. Pan American Health Organization (PAHO). Guideline for the preventive chemotherapy for the control of Taenia solium Taeniasis. https://iris.paho.org/bitstream/handle/10665.2/54800/9789275123720_eng.pdf?sequence=1&isAllowed=y. Updated September 2021. Accessed August 31, 2022.
  43. Park SY, Glaser C, Murray WJ, et al. Raccoon roundworm (Baylisascaris procyonis) encephalitis: case report and field investigation. Pediatrics. 2000;106(4):E56. [PubMed 11015551]
  44. Paul I, Gnanamani G, and Nallam NR, “Intestinal Helminth Infections Among School Children in Visakhapatnam,” Indian J Pediatr, 1999, 66(5):669-73.
  45. Pengsaa K, Sirivichayakul C, Pojjaroen-anant C, et al, “Albendazole Treatment for Giardia intestinalis Infections in School Children,” Southeast Asian J Trop Med Public Health, 1999, 30(1):78-83. [PubMed 10695793]
  46. Persichino JG, Miller LG. Pregnancy screening and monitoring of albendazole therapy for neurocysticercosis. Clin Infect Dis. 2018;67(11):1797-1798. [PubMed 29790912]
  47. Peters JM, Madhavan VL, Kazacos KR, Husson RN, Dangoudoubiyam S, Soul JS. Good outcome with early empiric treatment of neural larva migrans due to Baylisascaris procyonis. Pediatrics. 2012;129(3):e806-811. [PubMed 22311989]
  48. Salam RA, Haider BA, Humayun Q, Bhutta ZA. Effect of administration of antihelminthics for soil-transmitted helminths during pregnancy. Cochrane Database Syst Rev. 2015;(6):CD005547. [PubMed 26087057]
  49. Sawamura R, Fernandes MI, Peres LC, et al. Hepatic capillariasis in children: report of 3 cases in Brazil. Am J Trop Med Hyg. 1999;61(4):642-647. [PubMed 10548302]
  50. Siddiqui B, Faridi SH, Arif SH, Aslam M. Primary hydatid disease of the breast clinically masquerading as a galactocele: a case report. J Transl Int Med. 2015;3(2):82-84. [PubMed 27847893]
  51. Smego, RA, Bhatti S, Khaliq AA, et al, “Percutaneous Aspiration-Injection-Reaspiration Drainage Plus Albendazole or Mebendazole for Hepatic Cystic Echinococcosis: A Meta-Analysis,” Clin Infect Dis, 2003, 37(8):1073-83. [PubMed 14523772]
  52. Steinmann P, Utzinger J, Du ZW, et al. Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized controlled trial. PLoS One. 2011;6(9):e25003. doi: 10.1371/journal.pone.0025003. [PubMed 21980373]
  53. Tremoulet AH, Avila-Aquero ML, Paris MM, Canas-Coto A, Ulloa-Gutierrez R, Faingezicht I. Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children. Pediatr Inf Dis J. 2004;23(10):915-918. [PubMed 15602190]
  54. US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Updated November 21, 2019. Accessed January 22, 2020.
  55. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf.Updated December 9, 2019. Accessed January 22, 2020.
  56. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. December 2016. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf.
  57. White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018;66(8):e49-e75. doi: 10.1093/cid/cix1084. [PubMed 29481580]
  58. White AC Jr, Coyle CM, Rajshekhar V, et al. Reply to Garg et al, Smith et al, and Persichino and Miller. Clin Infect Dis. 2018;67(11):1798. [PubMed 29790917]
  59. Wilson ME, Lorente CA, Allen JE, et al, “Gongylonema Infection of the Mouth in a Resident of Cambridge, Massachusetts,” Clin Infect Dis, 2001, 32(9):1378-80. [PubMed 11303277]
  60. World Health Organization (WHO). Action against worms No 8: deworming young children. 2007. Available at https://www.who.int/intestinal_worms/resources/AAW_8_en/en/
  61. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
  62. World Health Organization (WHO). Guideline: preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. Geneva: World Health Organization; 2017. Available at https://www.who.int/intestinal_worms/resources/9789241550116/en/
  63. World Health Organization (WHO). Report of the informal consultation on hookworm infection and anaemia in girls and women. 1996. Available at https://www.who.int/intestinal_worms/resources/who_ctd_sip_96.1/en/
  64. World Health Organization (WHO). WHO guidelines on management of Taenia solium neurocysticercosis. Geneva: World Health Organization; 2021. [PubMed 34520139]
  65. World Health Organization (WHO). WHO Model Formulary for Children. 2010.
  66. Yereli K, Balcioğlu IC, Ertan P, et al, "Albendazole as an Alternative Therapeutic Agent for Childhood Giardiasis in Turkey," Clin Microbiol Infect, 2004, 10(6):527-9. [PubMed 15191380]
  67. Ziem JB, Kettenis IM, Bayita A, et al, "The Short-Term Impact of Albendazole Treatment on Oesophagostomum bifurcum and Hookworm Infections in Northern Ghana," Ann Trop Med Parasitol, 2004, 98(4):385-90. [PubMed 15228719]
Topic 9371 Version 249.0